Literature DB >> 17059426

A new vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with decreased stability of CYP2C9 enzyme.

R L D'Ambrosio, G D'Andrea, A Cafolla, F Faillace, M Margaglione.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17059426     DOI： 10.1111/j.1538-7836.2006.02261.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  12 in total

1.  Novel insight into the mechanism of the vitamin K oxidoreductase (VKOR): electron relay through Cys43 and Cys51 reduces VKOR to allow vitamin K reduction and facilitation of vitamin K-dependent protein carboxylation.

Authors:  Mark A Rishavy; Aisulu Usubalieva; Kevin W Hallgren; Kathleen L Berkner
Journal:  J Biol Chem       Date:  2010-10-26       Impact factor: 5.157

Review 2.  Pharmacogenetics in Jewish populations.

Authors:  Yao Yang; Inga Peter; Stuart A Scott
Journal:  Drug Metabol Drug Interact       Date:  2014

3.  Effect of the VKORC1 D36Y variant on warfarin dose requirement and pharmacogenetic dose prediction.

Authors:  Daniel Kurnik; Husam Qasim; Sophie Sominsky; Aharon Lubetsky; Noa Markovits; Chun Li; C Michael Stein; Hillel Halkin; Eva Gak; Ronen Loebstein
Journal:  Thromb Haemost       Date:  2012-08-07       Impact factor: 5.249

4.  Structure of a bacterial homologue of vitamin K epoxide reductase.

Authors:  Weikai Li; Sol Schulman; Rachel J Dutton; Dana Boyd; Jon Beckwith; Tom A Rapoport
Journal:  Nature       Date:  2010-01-28       Impact factor: 49.962

5.  VKORC1 pharmacogenomics summary.

Authors:  Ryan P Owen; Li Gong; Hersh Sagreiya; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2010-10       Impact factor: 2.089

6.  Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing.

Authors:  Dana C Crawford; Marylyn D Ritchie; Mark J Rieder
Journal:  Pharmacogenomics       Date:  2007-05       Impact factor: 2.533

7.  Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms.

Authors:  Michael R Langley; Jessica K Booker; James P Evans; Howard L McLeod; Karen E Weck
Journal:  J Mol Diagn       Date:  2009-03-26       Impact factor: 5.568

Review 8.  Warfarin pharmacogenetics.

Authors:  Nita A Limdi; David L Veenstra
Journal:  Pharmacotherapy       Date:  2008-09       Impact factor: 4.705

9.  VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians.

Authors:  Mohamed Hossam A Shahin; Larisa H Cavallari; Minoli A Perera; Sherief I Khalifa; Anne Misher; Taimour Langaee; Shitalben Patel; Kimberly Perry; David O Meltzer; Howard L McLeod; Julie A Johnson
Journal:  Thromb Haemost       Date:  2013-03-21       Impact factor: 5.249

10.  Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.

Authors:  Stuart A Scott; Lisa Edelmann; Ruth Kornreich; Robert J Desnick
Journal:  Am J Hum Genet       Date:  2008-01-17       Impact factor: 11.025
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.